The Current Good Manufacturing Practice for Finished Pharmaceuticals (211.192 production record reviews) requires the Quality Control team to review and approve the production of drug products and control records, including packaging and labelling. This is to ensure compliance with pre-established procedures before the release of a batch.
In case of unexpected discrepancies or in case a batch or any of its components does not meet the specifications outlined at the beginning, it should be thoroughly investigated, even if the batch has been distributed. Other batches of the same drug product or other drug products where a specific failure or discrepancy may have an impact must also be investigated. Even batches that are rejected based on an OOS result need to be investigated to see whether other batches of the same drug product or other products experience the same problems. A thorough, timely, unbiased, well-documented, and scientifically sound investigation needs to be done to identify the root cause and take necessary corrective and preventive action.
Usually, this is done in two phases – Phase I and Phase II.